Capozzi, Megan E.
Duke University
4 papers on CoChatORCID 0000-0002-7587-0663
Most cited papers
- Verified
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Willard, F. S., Douros, J. D., Gabe, M. B. N., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J. C., Stutsman, C., Cardona, G. R., et al. (2020) · JCI Insight
Diabetes Treatment and ManagementReceptor Mechanisms and Signaling
Cited by 541
- Verified
Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes
Capozzi, M. E., DiMarchi, R. D., Tschöp, M. H., Finan, B., & Campbell, J. E. (2018) · Endocrine Reviews
Diabetes Treatment and ManagementPancreatic function and diabetes
Cited by 153
- Verified
GIP mediates the incretin effect and glucose tolerance by dual actions on α cells and β cells
El, K., Gray, S. M., Capozzi, M. E., Knuth, E. R., Jin, E., Svendsen, B., Clifford, A., Brown, J. L., Encisco, S. E., Chazotte, B. M., et al. (2021) · Science Advances
Pancreatic function and diabetesDiabetes Treatment and Management
Cited by 132
- Verified
Pharmacological antagonism of the incretin system protects against diet-induced obesity
Svendsen, B., Capozzi, M. E., Nui, J., Hannou, S. A., Finan, B., Naylor, J., Ravn, P., D'Alessio, D. A., & Campbell, J. E. (2020) · Molecular Metabolism
Regulation of Appetite and ObesityDiabetes Treatment and Management
Cited by 67
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free